Navigation Links
InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
Date:6/10/2009

LOS ALTOS, Calif., June 10 /PRNewswire/ -- InteKrin Therapeutics Inc presented Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans demonstrating that once a day oral treatment with INT131 provides anti-diabetic efficacy consistent with maximal dose thiazolidinedione (TZD) therapy but with less hematocrit reduction and weight gain.

The 4 week double blind placebo controlled study of INT131 in Type 2 Diabetes Mellitus (T2DM) patients previously not on pharmacological therapy showed a dose dependent decrease in fasting plasma glucose (FPG) at 4 weeks, the primary endpoint of the study. This decrease was already statistically significant at 1 week for both low and high doses (1 mg and 10 mg) of INT131.

The efficacy measured at 4 weeks of 1 mg of INT131 treatment was comparable to the efficacy modeled for this patient population treated with the maximal approved doses of Actos(R) and Avandia(R), but in contrast the low dose INT131 group did not show the significant weight gain or fluid retention (measured by hematocrit drop) modeled for maximal dose TZDs. The high dose INT131 group showed about twice the decrease in FPG attained with low dose INT131, and a correspondingly greater efficacy compared to that modeled for maximal dose TZDs. Importantly, this greater efficacy was achieved with INT131 without greater weight gain or hematocrit drop than expected for maximal dose TZDs. INT131 was well tolerated in this study with no safety issues noted.

"These data are supportive of INT131 acting as a selective modulator of PPARgamma in T2DM patients," remarked Dr Alex DePaoli, Chief Medical Officer of InteKrin Therapeutics, who presented the data. "The key observation from this study is that INT131 is a potent insulin sensitizer that lowers fasting glucose as well as the maximal dose of the TZDs while mitigating the typical side effect profile."

"Translation of the nonclinical profile of INT131 into the clinic is an exciting validation of the selective PPAR modulator design of the molecule," added Dr Linda Higgins, Chief Scientific Officer of InteKrin Therapeutics. "INT131 retains or exceeds TZD potency and efficacy for glycemic lowering in rodent models of T2DM, while also showing remarkable safety in nonclinical studies of INT131 even at multiples of clinical exposures that far exceed those at which toxicities are observed with TZDs."

These Phase 2a study data provided the rationale for a double blind placebo controlled 24 week Phase 2b study of 4 doses of INT131 and 45 mg Actos(R) as active comparator in 360 T2DM patients. InteKrin completed enrollment of the study in March, 2009.

About INT131

INT131 is a next-generation, non-TZD insulin sensitizer and selective modulator of PPARgamma (SPPARM). INT131 belongs to a unique, non-TZD chemical class, and was purposely designed to retain the well validated and robust insulin sensitizing efficacy of PPARgamma while minimizing the typical side effects seen with the full agonists TZDs Actos(R) and Avandia(R). PPARgamma activation treats insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.


'/>"/>
SOURCE InteKrin Therapeutics Inc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. InteKrin Therapeutics Announces $20 Million Series C Financing
2. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
3. Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281
4. Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants
5. Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Incs. GCS-100 Molecule
6. Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers
7. Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
8. Echo Therapeutics Licenses Needle-Free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine
9. SXC Health Solutions announces agreements for pharmacy technology services with Prime Therapeutics LLC
10. Cephalon Acquires Controlling Interest in Arana Therapeutics
11. Cornerstone Therapeutics Announces Management Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... MN (PRWEB) , ... February 24, 2017 , ... ... of its newly designed TaskMate Go. Core benefits and advantages built into the ... and a stylish, functional look and feel. Ability to gain the benefits embedded ...
(Date:2/24/2017)... ... 24, 2017 , ... Dr. Ronald E. Hawkins, vice president ... of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean ... Dr. Bell comes to Liberty from the Ohio University Heritage College of Osteopathic ...
(Date:2/24/2017)... Melbourne, Australia (PRWEB) , ... February 24, 2017 , ... ... Press AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema ... post-traumatic stress disorder and his attempts to overcome them. , Schanssema, initially unsure ...
(Date:2/24/2017)... ... 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. ... Dyer started as the Chairman of the Management Committee when IFN was originally formed ... the recruitment of investor/owners and development of the business plan. He became the ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the ... The Jensie Gran Fondo of Marin. For the second year in a row, ... mineral-based sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)...  Xynomic Pharmaceuticals, Inc., an oncology drug research ... acquired exclusive worldwide rights to develop, manufacture and ... targeting hematological and solid tumors. To ... 2 clinical trials of Abexinostat in US, EU ... been completed, demonstrating that Abexinostat is clinically active ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
(Date:2/23/2017)... 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a medical ... products for the urology market, will release financial results ... 31, 2016 before the market open on Thursday, March ... a conference call and webcast to discuss its financial ... at 11:00 a.m. Eastern Time (10:00 a.m. Central Time). ...
Breaking Medicine Technology: